The capital structure is characterized by severe equity erosion, with accumulated losses reaching $64.4 million as of 2026Q3, while the absence of long-term debt reflects limited access to traditional credit markets.
| Total Current Assets | 3.7M | 4.18M | 455.24K | 5.84M | 14.41M | 2.91M | 1.81M | 1.5M | 2.42M | 57.29K | 5.61K |
| Cash & Short-Term Investments | 2.71M | 3.95M | 376.05K | 5.14M | 14.06M | 1.93M | 90.28K | 42.61K | 545K | 4.98K | 1.14K |
| Cash Only | 2.71M | 3.95M | 376.05K | 5.14M | 14.06M | 1.93M | 90.28K | 42.61K | 545K | 4.98K | 1.14K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 16.21K | 194.28K | 285.35K | 424.35K | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | -16.21K | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.7K | 3.54K |
| Total Non-Current Assets | 342.55K | 425.61K | 176.35K | 79.84K | 102.91K | 352.5K | 0 | 0 | 0 | 75K | 25K |
| Property, Plant & Equipment | 342.55K | 425.61K | 176.35K | 79.84K | 102.91K | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 352.5K | 0 | 0 | 0 | 75K | 25K |
| Total Assets | 4.04M | 4.6M | 631.59K | 5.92M | 14.52M | 2.91M | 1.81M | 1.5M | 2.42M | 132.29K | 30.61K |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - | - | - | - |
| Asset Growth % | 906.15% | 628.8% | -89.32% | -59.25% | 398.4% | 60.56% | 20.86% | -37.88% | 1726.26% | 332.13% | - |
| Total Current Liabilities | 1.86M | 634.76K | 3.23M | 2.87M | 1.16M | 899.64K | 992.31K | 1.18M | 96.72K | 717.22K | 30.72K |
| Accounts Payable | 1.86M | 634.76K | 2.93M | 2.87M | 1.16M | 503.59K | 929.64K | 1.1M | 90.09K | 125.97K | 2.6K |
| Days Payables Outstanding | 4K | 4.57K | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 300.71K | 0 | 0 | 335.3K | 63 | 79 | 0 | 591.26K | 3.12K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | -63 | -79 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | -63 | -79 | 0 | 0 | 25K |
| Current Ratio | 1.99x | 6.58x | 0.14x | 2.03x | 12.37x | 3.24x | 1.83x | 1.27x | 24.98x | 0.08x | 0.18x |
| Quick Ratio | 1.99x | 6.58x | 0.14x | 2.03x | 12.37x | 3.26x | 1.83x | 1.27x | 24.98x | 0.08x | 0.18x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 1.16M | 0 | 0 | 1.1M | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.86M | 634.76K | 3.23M | 2.87M | 1.16M | 899.64K | 992.31K | 1.18M | 96.72K | 717.22K | 30.72K |
| Total Debt | 0 | 0 | 300.71K | 0 | 0 | 335.3K | 63 | 79 | 0 | 591.26K | 3.12K |
| Net Debt | -2.71M | -3.95M | -75.33K | -5.14M | -14.06M | -1.59M | -90.22K | -42.53K | -545K | 586.28K | 1.98K |
| Debt / Equity | 0.00x | - | - | - | - | 0.17x | 0.00x | 0.00x | - | - | - |
| Debt / EBITDA | -0.00x | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.39x | - | - | - | - | - | - | - | -1267.44x | - | - |
| Interest Coverage | -1634.50x | -249.42x | -983.86x | -1930.92x | -264.81x | -31.18x | - | - | - | - | - |
| Total Equity | 2.18M | 3.97M | -2.59M | 3.05M | 13.35M | 2.01M | 821.71K | 316.92K | 2.32M | -584.93K | -106 |
| Equity Growth % | 773.6% | 252.97% | -185.18% | -77.19% | 563.28% | 144.97% | 159.28% | -86.34% | 496.51% | -551720.75% | - |
| Book Value per Share | 0.57 | 8.80 | -34.51 | 42.16 | 202.30 | 37.40 | 15.57 | 7.27 | 68.98 | -27.42 | - |
| Total Shareholders' Equity | 2.18M | 3.97M | -2.59M | 3.05M | 13.35M | 2.01M | 821.71K | 316.92K | 2.32M | -584.93K | -106 |
| Common Stock | 380 | 78 | 69 | 9.69K | 9.55K | 6.74K | 6.48K | 6.19K | 4.95K | 3.29K | 4.64K |
| Retained Earnings | -64.44M | -58.54M | -54.02M | -44.07M | -29.19M | -16.83M | -11.79M | -7.38M | -2.51M | -1.58M | -11.58K |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | -14.88M | -14.88M | -14.88M | -14.98M | -15M | -4.95K | 0 | -3K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity and dilution
According to recent financial disclosures, ALZN's cash and equivalents have declined to $2.7 million as of 2026Q3, representing a significant contraction from the $5.6 million reported in 2026Q1, which underscores the company's precarious liquidity position as it continues to fund intensive clinical development programs.
The current ratio of 1.99 suggests a superficial buffer, yet this metric is heavily influenced by the rapid depletion of cash reserves relative to current liabilities. Investors should monitor the burn rate closely, as the current cash balance appears insufficient to support long-term Phase II trial requirements without immediate external financing.
As reported in financial statements, the company's equity base has been severely eroded by accumulated losses, which reached $64.4 million by 2026Q3, indicating that the firm's capital structure is primarily sustained by periodic equity issuances rather than internal value creation or retained earnings growth.
The negative trend in retained earnings highlights the structural inability of the business to generate self-sustaining capital. This reliance on equity markets for survival suggests that existing shareholders face a high probability of continued dilution as the company attempts to bridge its funding gap.
Based on reported figures, ALZN's total assets have contracted from $6.3 million in 2026Q1 to $4.0 million in 2026Q3, signaling a deteriorating balance sheet trajectory that mirrors the company's ongoing struggle to maintain operational momentum while managing a high-cost, pre-revenue clinical research pipeline.
The consistent decline in total assets suggests that the company is consuming its resource base faster than it can replenish it through capital raises. This trajectory warrants further investigation into the sustainability of the current R&D model, as the asset base provides little protection against potential clinical or regulatory setbacks.
Data from recent filings reveals that the absence of long-term debt is not a sign of financial strength, but rather a reflection of the company's inability to access traditional credit markets, forcing a total reliance on dilutive equity financing to cover its ongoing operating cash burn.
While the lack of debt avoids interest expense, it leaves the company entirely exposed to the volatility of equity markets. Investors should be wary that the headline absence of leverage masks the underlying risk of a 'death spiral' financing structure, which could severely impair shareholder value if clinical milestones are delayed.
Quick answers to the most common questions about buying ALZN stock.
As of 2025, Alzamend Neuro, Inc. (ALZN) had total assets of $4.6M including $4.2M in current assets.
Alzamend Neuro, Inc. (ALZN) carries total debt of $0.0M, offset by $3.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Alzamend Neuro, Inc. (ALZN) has total shareholders' equity (book value) of $4.0M ($8.80 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Alzamend Neuro, Inc. (ALZN) reported a current ratio of 6.58x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.